Catumaxomab
Monoclonal antibody / From Wikipedia, the free encyclopedia
Catumaxomab[1] (trade name Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Trifunctional antibody |
Source | Rat/mouse hybrid |
Target | EpCAM, CD3 |
Clinical data | |
Trade names | Removab |
AHFS/Drugs.com | International Drug Names |
License data | |
Routes of administration | intraperitoneal infusion |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
NY (what is this?) (verify) |
Close